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AbstrAct
Introduction We summarise an ethically approved 
protocol for the development of an experimental human 
challenge colonisation model. Globally Bordetella pertussis 
is one of the leading causes of vaccine-preventable death. 
Many countries have replaced whole cell vaccines with 
acellular vaccines over the last 20 years during which 
pertussis appears to be resurgent in a number of countries 
in the developed world that boast high immunisation 
coverage. The acellular vaccine provides relatively short-
lived immunity and, in contrast to whole cell vaccines, 
may be less effective against colonisation and subsequent 
transmission. To improve vaccine strategies, a greater 
understanding of human B. pertussis colonisation is 
required. This article summarises a protocol and does not 
contain any results. 
Methods and analysis A controlled human colonisation 
model will be developed over two phases. In phase A, 
a low dose of the inoculum will be given intranasally to 
healthy participants. This dose will be escalated or de-
escalated until colonisation is achieved in approximately 
70% (95% CI 47% to 93%) of the exposed volunteers 
without causing disease. The colonisation period, shedding 
and exploratory immunology will be assessed during a 
17-day inpatient stay and follow-up over 1 year. The dose 
of inoculum that achieves 70% colonisation will then be 
confirmed in phase B, comparing healthy participants 
exposed to B. pertussis with a control group receiving a 
sham inoculum.
Ethics and dissemination This study has been approved 
by the ethical committee reference: 17/SC/0006, 24 
February 2017. Findings will be published in peer-
reviewed open access journals as soon as possible.
IntroductIon
Pertussis, also called whooping cough, is an 
acute bacterial infection caused by Bordetella 
pertussis (Bp), an exclusively human pathogen. 
Although it can affect people of all ages, young 
unimmunised infants are the most vulnerable 
group with the highest rates of complications 
and death.1 In 1999, there were an estimated 
48.5 million cases with pertussis in children 
worldwide and 295 000 deaths,2 but based on 
seroepidemiological prevalence studies, the 
number of asymptomatic Bp infections may 
be much higher.3 By 2013, mortality fell to 
about 60 600 (IQR 22 300–136 800) children 
per year, still making it one of the leading 
causes of vaccine-preventable death.4
Pertussis vaccines have been included in 
National Immunisation Programmes since 
their introduction in the 1940s–1950s. Acel-
lular pertussis (aP) vaccines have a favourable 
reactogenicity profile in comparison with 
whole-cell pertussis (wP) vaccines and are 
currently mostly used in industrialised coun-
tries to immunise against pertussis.5 However, 
many countries in the developed world that 
boast high immunisation coverage have seen 
an increase in the incidence of pertussis 
over the past 20 years.6 Five main hypotheses 
have been proposed to contribute to this 
resurgence: (1) rapid waning of immunity 
following vaccination, especially with aP,7 (2) 
the very different immune response profile 
induced by aP compared with wP vaccines,8 
Investigating Bordetella pertussis 
colonisation and immunity: protocol for 
an inpatient controlled human 
infection model
Hans de Graaf,1 Diane Gbesemete,1 Andrew R. Gorringe,2 
Dimitri A. Diavatopoulos,3 Kent E. Kester,4 Saul N. Faust,5 Robert C. Read6
To cite: de Graaf H, 
Gbesemete D, Gorringe AR., 
et al.  Investigating Bordetella 
pertussis colonisation and 
immunity: protocol for an 
inpatient controlled human 
infection model. BMJ Open 
2017;7:e018594. doi:10.1136/
bmjopen-2017-018594
 ► Prepublication history and 
additional material for this 
paper are available online. To 
view these files, please visit 
the journal online (http:// dx. doi. 
org/ 10. 1136/ bmjopen- 2017- 
018594).
Received 10 July 2017
Revised 28 August 2017
Accepted 11 September 2017
For numbered affiliations see 
end of article.
correspondence to
Dr Hans de Graaf;  
 h. de- graaf@ soton. ac. uk
Protocol
strengths and limitations of this study
 ► Close inpatient observation after Bordetella pertussis 
exposure allows close monitoring of volunteer 
safety, prevents transmission to people at risk of 
pertussis disease and provides the opportunity to 
assess shedding of B. pertussis.
 ► The proposed dose escalation schedule is designed 
to optimise volunteer safety.
 ► As part of the Periscope consortium, it will be possible 
to compare the immunology and microbiology 
results of this human challenge study with vaccine-
induced immunity and results of animal challenge 
studies.
 ► The individual variation and the low number of 
participants might influence the external validity of 
the results.
 ► Aiming for 70% colonisation may be suboptimal for 
future vaccine efficacy studies using this model.
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Figure 1 Escalating or de-escalating the dose of the inoculum according to colonisation frequency.
(3) adaptation of Bp to escape protective immunity, (4) 
low vaccine coverage and (5) less effective reduction of 
transmission from infected individuals vaccinated with 
aPs.9 The latter is supported by baboon studies that have 
demonstrated that vaccination with aP prevents severe 
disease but does not prevent asymptomatic infection, 
that is, colonisation.10 Studies in mice are consistent with 
these findings and demonstrate that protective immu-
nity is more effective and persistent when induced by 
natural infection or wP than by aP.11 To study the patho-
genesis of pertussis, a variety of animal models have been 
used, including mice, rabbits, guinea pigs and newborn 
piglets.12 However, there are still important knowledge 
gaps relating to human immunity to Bp, and it is not 
clear to what extent these observations in animal models 
translate into clinical practice. This paucity of knowledge 
hampers the development of improved vaccines and the 
design of better vaccination strategies against pertussis in 
infants, adolescents and adults.
The deliberate infection of human volunteers with 
micro-organisms has contributed uniquely to our under-
standing of the pathogenesis, immune responses and 
the treatment and prevention of numerous microbial 
diseases including pneumococcal disease,13 influenza, 
cholera, typhoid and hepatitis.14 We aim to develop a safe 
human challenge colonisation model to allow a more 
thorough understanding of the immune response against 
wild-type Bp and to facilitate development of bioassays 
and next-generation pertussis vaccines.
MEthods
This is a controlled human infection study consisting of two 
phases: phase A: development of a Bp human challenge 
colonisation model and phase B: development of a modi-
fied Bp human challenge colonisation model in which we 
will compare participants receiving the standard inoculum 
(SI) with a control group receiving a sham inoculum. This 
article summarises the protocol for phase A.
Phase A will be a dose-finding phase in which the dose 
of inoculum will be escalated or de-escalated to find the 
SI, defined as the dose of Bp that will safely cause coloni-
sation in approximately 70% (95% CI 47% to 93%) of the 
exposed participants. Colonisation will be defined as a posi-
tive culture of Bp from the nasal washspecimen between 
day 0 and 14. After five participants have received the inoc-
ulum, colonisation will be assessed, and the following five 
participants will receive either the same dose or an esca-
lated or decreased dose (figure 1). Once a dose of inoc-
ulum achieves a colonisation rate of 70%, then that dose 
will be used to inoculate further participants until a total 
of 10 participants have been colonised. This will require 
inoculation of approximately 14 participants with that dose, 
which will then be defined as the SI dose.
The various samples (nasopharyngeal swab, throat swab, 
nasal wash and nasal fluid sample) will be compared to 
identify the technique that yields the highest sensitivity of 
Bp detection to inform the design of phase B. The serocon-
version rate will be measured comparing preinoculation 
and postinoculation serum samples of participants infected 
after receiving the SI. Seroconversion will be defined as a 
threefold rise in anti-pertussis toxin (PT) IgG titre (IU/
mL) from day 0 to day 28. We will then identify the ‘colo-
nisation period’, which is defined as the earliest day after 
inoculation on which colonisation of the nasopharynx (as 
detected by the most sensitive technique) is observed in 
100% of those volunteers who subsequently seroconvert at 
day 28. The colonisation period will be used in the protocol 
for phase B to minimise the duration of infection prior to 
eradication of Bp by antibiotics.
study objectives
The primary objective of phase A of this study is to deter-
mine the dose of the SI in participants who do not have 
group.bmj.com on February 5, 2018 - Published by http://bmjopen.bmj.com/Downloaded from 
 3de Graaf H, et al. BMJ Open 2017;7:e018594. doi:10.1136/bmjopen-2017-018594
Open Access
Table 1 Objectives and endpoints of the study
Objectives Endpoints
1A To determine the dose of the standard 
inoculum in participants who do not have 
evidence of recent Bp exposure—safety
Safety endpoints:
- Occurrence of possible or confirmed Bp disease within the study period
- Occurrence of unsolicited adverse events within the study period
- Occurrence of serious adverse events within the study period
1B To determine the dose of the standard 
inoculum in participants who do not have 
evidence of recent Bp exposure—70% 
colonisation
Microbiologically proven Bp colonisation by positive culture of Bp from a 
nasal wash sample taken between time points day 0 and 14 after being 
challenged on day 0
2x To evaluate accuracy of the inoculum 
dosing
Estimation of the actual challenge dose in comparison with the prescribed 
challenge dose by viable count (cfu/mL) of residual inoculum following 
inoculation of each participant
3 To describe the human physiological 
response to Bp challenge in those 
developing or not developing infection
Description of the clinical course after challenge using, for example:
Clinical and laboratory observations such as temperature (°C), systolic 
blood pressure (mm Hg), diastolic blood pressure (mm Hg), heart rate 
(beats/min), respiratory rate (breaths/min), O2 saturation in blood (%), CRP 
(mg/L), WCC (109/L), lymphocyte count (109/L) at various time points
4 To determine the colonisation period: the 
earliest day after inoculation at which 
colonisation of the nasopharynx (as 
detected by culture) is observed in 100% 
of those participants who subsequently 
seroconvert at day 28
A threefold rise in anti-PT IgG titre
(IU/mL) from day 0 to day 28 will be used as a marker of seroconversion. 
Colonisation will be detected by positive culture of Bp from a 
nasopharyngeal swab taken between time points day 0 and 14
5 To determine the characteristics of bacterial 
dynamics after challenge
Microbiological assays to detect and characterise Bp dynamics after 
challenge in nasopharyngeal swabs (culture, qPCR and microbiome 
analyses), nasal wash (culture including semiquantitative method using 
cfu count/mL, and precision quantification with qPCR) and sequencing of 
isolates at various time points
6 To assess environmental shedding of 
Bp following nasal inoculation of healthy 
participants with Bp.
Daily microbiological assays from day 0 to 16 to detect Bp on surface 
contact (culture and PCR), air sampling (PCR) fingertip culture (culture Bp 
and PCR), cough box (culture Bp, particle size during various activities: 
talking, coughing and singing)
7 To determine the eradication frequency of 
Bp after a 3-day course of azithromycin
Microbiological assays after eradication in nasopharyngeal swabs 
(culture, qPCR and microbiome analyses), nasal wash (culture including 
semiquantitative method using cfu count/mL, qPCR) on days 15 and 16
8 To describe the human immune response to 
challenge, including innate, humoural, cell-
mediated and mucosal responses.
Immunological assays to measure innate, humoural, cell-mediated and 
mucosal responses to challenge in blood (anti-PT IgG (IU/mL), anti-FHA 
IgG (IU/mL), anti-PRN IgG (IU/mL), anti-FIM IgG (IU/mL), nasal washes (T 
cell/B cell analyses), nasal fluid samples (cytokines) and saliva (Bp-specific 
IgA (IU/mL)) samples, comparing day 0 with days 1, 3, 4, 7, 9, 11 and 14 
and weeks 4, 8, 26 and 52.
Bp, B. pertussis; cfu, colony-forming units; CRP, C reactive protein; FIM, fimbriae; FHA, filamentous haemagglutinin; IU, international units; 
PCR, polymerase chain reaction; PRN: pertactin; PT, pertussis toxin; qPCR, quantitative PCR; WCC: white cell count.
evidence of recent Bp exposure. The SI is defined as the 
dose of Bp causing colonisation in approximately 70% of 
the participants between day 0 and 14 without causing Bp 
disease after being challenged with this dose at day 0. An 
endpoint of 70% is used to avoid, if possible, a ‘saturating 
dose’ that results in non-physiological colonisation by Bp 
in participants but still induces sufficiently high colonisa-
tion rates to enable potential future vaccine efficacy trials. 
Secondary endpoints will explore the ability to dose the 
inoculum accurately, the prechallenge and postchallenge 
Bp-specific immunity in healthy participants and the 
environmental shedding of Bp following nasal inocula-
tion (see table 1). Feedback and recommendations from 
Patient and Public Involvement, in addition to participant 
questionnaires from previous malaria human challenge 
studies performed in Southampton, have been incorpo-
rated into this study.
challenge strain
The Bp isolate to be used in this human colonisation 
model is B1917, which is representative of current isolates 
in Europe.15 16 The strain, isolated in 2000 from a Dutch 
patient with Bp disease, is characterised as ptxP3-ptxA1-
prn2-fim3-2, fim2-1 MLVA27, PFGE BpSR11 and expresses 
pertactin, PT and filamentous haemagglutinin. This 
strain has been extensively characterised in the mouse 
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model as well as by proteomics and transcriptomics and 
has a closed genome available.16 It is fully sensitive to 
azithromycin in vitro.
The inoculum has been prepared by Q Biologicals 
(Ghent, Belgium) according to good manufacturing prac-
tice (GMP) standard in licenced GMP facilities and using 
a process free of animal-derived products. The identity 
and purity of the cell bank have been confirmed, in addi-
tion to any other quality specifications agreed within the 
consortium and needed for compliance with regulatory 
requirements. Before intranasal inoculation, there will 
be no further culture of the challenge inoculum at the 
clinical site. The dose and purity of the inoculum will be 
determined after inoculation for quality assessment.
study setting
This is one of several other clinical and preclinical studies 
of the Periscope consortium (http:// periscope- project. 
eu/ consortium/), which brings together internationally 
renowned scientists with many years of experience in Bp 
research, clinical trials, bioinformatics, immunology and 
public health. The aim of the consortium is to promote 
scientific and technological innovation in pertussis 
vaccine development and to foster the creation of a labo-
ratory and scientific network that facilitates the testing 
and helps expedite the development of novel pertussis 
vaccines in Europe.
The study will be conducted by the University of South-
ampton in the National Health Institute for Health 
Research Clinical Research Facility (CRF) Southampton.
recruitment
Participants will be recruited via the following:
 ► Southampton CRF and Periscope websites—informa-
tion about the study will be available on the website 
with a downloadable volunteer information sheet
 ► posters in public places, including buses and trains, 
university campus, student bars, halls of residence, 
health centres and so on with the agreement of the 
owner/proprietor
 ► newspapers or other literature for circulation
 ► press release
 ► Clinical Research Update magazine
 ► a post on a Twitter, Facebook or Gumtree account 
owned and operated by our group
 ► email distribution to individuals who have already 
expressed an interest in taking part in any clinical trial 
at the CRF Southampton
 ► Southampton CRF Database of Healthy Volun-
teers: individuals from this database have previously 
expressed an interest in receiving information about 
future studies for which they may be eligible.
A recruitment and volunteer management plan has 
been formulated to prioritise and coordinate these strat-
egies. Potential volunteers who are interested will be sent 
the volunteer information sheet and will be invited for 
a screening visit. During this visit, they will be given an 
opportunity to discuss the study questions and complete a 
preconsent questionnaire to ensure they understand the 
study. The informed consent procedure includes specific 
infection prevention information regarding the measures 
that are taken to prevent transmission during admission 
to the research unit. Once consent has been given, their 
eligibility will be assessed. This will include a general 
health questionnaire, which is a screening tool to iden-
tify common psychiatric conditions. The medical history 
will be checked with the general practitioner. Participants 
will be offered reimbursement for their time, travel and 
inconvenience.
Eligibility criteria
Healthy volunteers, men and women, aged 18–45 years 
without known or suspected recent pertussis infection 
(anti-PT IgG >20 IU/mL) will be recruited for phase A. 
Care will be taken not to recruit from vulnerable groups 
(mental health or other impaired capacity issues). 
Specific inclusion and exclusion criteria can be found in 
the online supplementary table 1 . Female volunteers are 
required to use an effective form of contraception for the 
duration of their participation in this study. These criteria 
should minimise the risk of complicated disease or trans-
mission of Bp to risk groups and aim to select a homoge-
nous group that will be able to adhere to the scheduled 
admission and follow-up visits.
Interventions
The start of volunteer participation is defined as the 
screening visit. The end of volunteer participation is 
defined as the last visit. The duration of involvement in 
this study from screening will be approximately 56 weeks. 
A detailed schedule of the interventions is shown in 
table 2.
A week before the challenge, nasal samples will be 
collected (see figure 2). On the day of the challenge, the 
participant will be admitted to a designated area in the CRF 
and will have access to a dedicated individual bedroom, 
shared toilet, shower and recreational areas during their 
stay in the facility. Participants will be required to wear a 
surgical mask covering their nose and mouth when outside 
their personal room, for example, in the recreational room, 
unless outside in open air. Participants will be allowed to 
leave the CRF for a maximum of 2 hours twice a day, during 
the daytime. When outside the CRF, participants will be 
asked to adhere to infection prevention rules based on 
Public Health England guidelines. These include avoiding 
contact with people at risk of pertussis, avoiding direct face-
to-face contact and wearing a surgical face mask when inside. 
When they leave or come back to the designated area, they 
will be escorted by a member of the study team. The Bp 
inoculum will be prepared and administered following 
study-specific standard operating procedures that are based 
on previous human challenge studies using nasal inocula-
tion with Neisseria lactamica.17 18 One phial of inoculum will 
be removed from the freezer, thawed and diluted to the 
required inoculum dose. The participant will be positioned 
supine with neck extended, mouth open and breathing 
group.bmj.com on February 5, 2018 - Published by http://bmjopen.bmj.com/Downloaded from 
 5de Graaf H, et al. BMJ Open 2017;7:e018594. doi:10.1136/bmjopen-2017-018594
Open Access
Table 2 Scheduled events and interventions
Day −30 −7 0 1 2 3 4 5 7 9 11 14 15 16 28 56 183 365
Visit x x x x x x
Admission
Inoculum x
Bloods x x x x x x x x x x x x x x
Urine x x
ECG x
Nasal wash x x x x x x x x x x x
Nasal fluid sample 2x 2x 2x 2x 2x 2x 2x 2x 2x 2x 2x 2x 2x 2x
Nasopharyngeal swab x x x x x x x x x x x
Throat swab x x x x x x x x x
Saliva x x x x x x x x x
Antibiotic therapy x x x
Figure 2 Visits and admission design.
normally through their mouth. An inoculum of 0.5 mL will 
be gently expelled into each nostril, while the participant is 
positioned with mouth open, neck extended and breathing 
normally through their mouth. After the inoculum is admin-
istered, the inoculum residuum will be diluted and cultured 
for 5 days on Bordetella selective medium for determination 
and viable counts of Bp and on non-selective medium to 
assess purity of the inoculum.
During admission, clinical observations and symptoms of 
possible early pertussis disease such as rhinorrhoea, nasal 
congestion, epistaxis, sneezing, ear pain, eye pain, sore 
throat, cough, dyspnoea, feeling generally unwell, tiredness 
and headache will be reviewed six times per day. Regular 
nasal, mouth, throat and blood samples will be taken to 
assess the microbial dynamics and the host response to 
the challenge. Environmental samples will be taken to 
assess shedding. These include cultures and quantitative 
polymerase chain reaction of: face masks, contact areas 
in the personal room, air sampling of the personal room 
and during aerosol producing activities. Nasopharyngeal 
samples will be requested from CRF staff members with 
participant contact to monitor transmission of viable Bp.
In phase A, azithromycin 500 mg will be given once a 
day for 3 days to eradicate possible Bp colonisation on day 
14 or to treat possible early stage Bp disease before day 
14 following national guidelines.19 After start of the treat-
ment, participants will remain in the hospital for another 
48 hours to assess eradication success and environmental 
shedding after eradication.
A nasopharyngeal swab will be taken prior to discharge, 
which will be 48 hours after the start of eradication 
therapy. If this sample is positive for Bp within 5 days, the 
course of azithromycin will be repeated. Follow-up visits 
will take place at week 4, 8, 26 and 52.
If, following inoculation, the participant develops 
symptoms of early pertussis disease, the participant will be 
given azithromycin according to Public Health England 
treatment guidelines. This will be done following a 
predefined treatment algorithm (see figure 3), which 
is designed to exclude trivial viral infection or transient 
and non-specific upper respiratory tract symptoms. 
After treatment, the participant will continue to be 
included in the study, and specimens will be collected 
as if they had received eradication treatment at day 14 
per protocol.
safety
Our priority is to develop this model without causing 
harm to the individual or the environment. An important 
facet of a safe model will be to limit participant exposure 
to Bp to the minimum dose and number of days required 
to signal successful colonisation. Safety considerations in 
the protocol include:
1. The dose of the inoculum will start low and will be 
modified to the lowest dose required to effectively 
establish colonisation with regular reviews of the 
available safety data by the study steering committee 
and the external safety committee.
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Figure 3 Actions to be taken when symptoms of early Bordetella pertussis disease are suspected. CRP, C reactive protein; PI, 
principal investigator; URTI, upper respiratory tract infection; WCC, white cell count.
2. The timing of eradication will be modified to optimise 
the safety of the participants by exposing them to the 
minimal effective period of colonisation.
3. The incubation time for the catarrhal phase is un-
known but is estimated to be 7–22 days. After inoc-
ulation of the participants, there will therefore be a 
moderate risk of symptom development because erad-
ication therapy will initially be given at day 14.
4. If a participant shows signs of possible disease, there 
will be a low threshold to eradicate colonisation.
5. Bp disease in adults is often atypical and relatively 
mild. Treatment is not thought to reduce the duration 
of coughing in natural infection, but adults with nat-
ural infection will not usually receive treatment until 
a late stage of the disease, if at all. Early treatment (as 
proposed in this study) is considered more likely to 
reduce symptoms quickly.
6. The likelihood of severe disease is extremely low, and 
the risk of harm to the participants, staff and others 
can be minimised by admitting the participants as in-
patients in the Southampton CRF, which is an Nation-
al Institute for Health Research (NIHR) facility spe-
cifically funded to conduct higher risk experimental 
medicine in a safe National Health Service environ-
ment. Household contacts will not be asked to pro-
vide informed consent, but volunteers with household 
members within the risk groups for pertussis disease 
will be excluded from the study.
7. All healthcare workers involved in this study will be 
vaccinated against Bp at least 2 weeks before working 
with participants that have received the inoculum 
unless they have been vaccinated against Bp in the 
last 5 years.20
An external safety committee of independent infec-
tious disease experts will assess the safety of study after 
every five participants and advise on the continuation of 
the study.
sample size
Phase A is a dose-finding study, and the sample size has 
been estimated with the assumption that we will colo-
nise no, or only a few, participants at the initial low dose, 
allowing for escalation of the dose based on colonisa-
tion frequency and safety parameters. We are aiming to 
achieve colonisation and seroconversion in 10 partici-
pants with the SI dose of Bp.
statistical analysis
Formal statistical comparisons of colonisation/serocon-
version will not be carried out in phase A. In this dose-
finding phase, decisions to escalate or de-escalate the 
dose will be based on the results accumulating over the 
progression of the study.
Ethics and dissemination
In the United Kingdom and the European Union , an 
experimental human challenge study with a wild-type bacte-
rium falls outside the European Clinical Trials Directive.14 
Participants in challenge trials are healthy volunteers who 
do not obtain direct health benefit from participation. 
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Potential volunteers will be informed of all conceivable 
risks and have adequate time to decide on their individual 
participation in relation to the risks involved and financial 
compensation for the time and inconvenience of taking 
part. Medical ethicists have argued that it is a healthy adult’s 
right to self-determine their participation in such trials in 
relation to the risk (Controlled human infection studies 
in the development of vaccines & therapeutics, Wellcome 
Trust Scientific Conference, January 9–11, 2013, University 
of Cambridge, UK).
The protocol has been reviewed by independent 
peer reviewers including experts from Public Health 
England and worldwide experts on pertussis within the 
Periscope consortium (www. periscope- project. eu) who 
have assessed the safety and the quality of the study, the 
study design and the feasibility of the study objectives. 
The protocol has been reviewed and approved by the 
South Central – Oxford A Research Ethics Committee 
(REC reference: 17/SC/0006, 24 February 2017) and 
the UK Health Research Authority (IRAS project ID: 
219496, 1 March 2017). Findings will be published in 
peer-reviewed open access journals as soon as possible. 
The final protocol for phase B will be presented as a 
substantial protocol amendment, because it will be based 
on the SI and colonisation period identified in phase A 
as well as the outcome of the exploratory immune assays 
performed during this phase.
dIscussIon
To the best of our knowledge, this will be the first adult 
human challenge study with wild type Bp. A paediatric Bp 
human challenge study was performed in 1933 in which 
two naive and two vaccinated children were exposed to 
140 cfu of intranasal Bp.21 While the vaccinated children 
did not develop whooping cough, the naive children 
developed severe disease including anorexia, fever, severe 
paroxysmal cough, leucocytosis, lymphocytosis and posi-
tive cough plate cultures. They received no treatment and 
improved by day 35. This study confirmed that pertussis 
disease is caused by the bacillus of Bordet and Gengou 
and could be prevented by the experimental Bp vaccine 
that was used.
In a recent first in human study, healthy volunteers 
were given a live attenuated Bp strain as a nasal vaccine.22 
The inoculated strain was genetically modified; dermone-
crotic toxin and tracheal cytotoxin were removed, and 
PT was genetically detoxified by two independent muta-
tions, removing the toxic activity of PT without affecting 
its immunogenic properties. Three groups, each of 12 
participants, were inoculated with 103, 105 or 107 colony 
forming units, respectively. Colonisation was seen in one 
subject in the low dose, one in the medium dose and five 
in the high dose group. Adverse events occurred in similar 
frequency in all groups, including the placebo group and 
were found to be trivial. The effect of the genetic changes 
on the ability to colonise are unknown, but it is expected 
to have a significant effect on colonisation.
The inoculum required to colonise previously vacci-
nated adults exposed to natural infection with Bp is 
unknown but is assumed to be higher than that used 
in the paediatric challenge study because previously 
exposed and vaccinated adults are included. The initial 
inoculum dose used in our study (1000 cfu) has been 
chosen as a dose low enough to be assumed to be safe but 
high enough to allow accurate monitoring.
This model presumes that Bp disease is preceded by 
colonisation. Direct evidence for this has proven hard 
to obtain in surveillance studies.23 24 Potential reasons 
for this are the use of inadequate sampling methods or 
insufficiently sensitive assays, or that colonisation is a very 
short phenomenon and often missed in a cross-sectional 
study. Seroprevalence studies do show there is a natural 
boosting of anti-PT IgG levels, suggesting asymptomatic 
infection/colonisation is quite frequent.25–27
Results of two previous studies demonstrated statisti-
cally significant correlations between protection against 
pertussis disease and the presence of anti-PT IgG in 
pre-exposure sera.28 29 Because of this, we will exclude 
volunteers with a high anti-PT IgG in phase A, although 
there is no evidence that high anti-PT IgG levels correlate 
with protection against colonisation. In phase B, this 
will not be an exclusion criterion, and the correlation 
between anti-PT IgG levels and protection against coloni-
sation will be assessed.
To minimise the risk for the participant, this controlled 
infection study is not a disease model, as was the case 
with many other challenge studies,30 31 but a colonisation 
model. The risk of symptom development in phase A is 
moderate rather than low because eradication therapy is 
not planned to be given until day 14 to allow an adequate 
immune response to develop. Eradication therapy will 
be given earlier if symptoms develop that are suggestive 
of pertussis disease. This approach is considered to be 
acceptable because the risk of severe disease in healthy 
adults, who are previously vaccinated and probably natu-
rally exposed to Bp, is extremely low.32 33 Antibiotic treat-
ment is known to be effective at eradicating Bp if given 
early after diagnosis but does not alter the subsequent 
clinical course of the illness,34 especially if administered 
beyond 2–3 weeks after the onset of symptoms. In this 
study, treatment will be given at an early stage of the infec-
tion, which we predict will have a more positive effect on 
the disease course.
We have implemented comprehensive transmission 
prevention measures, including an inpatient stay of 17 
days. The shedding of Bp, the colonisation frequency 
and colonisation period will be evaluated during phase 
A alongside the host immune response to inform a more 
directed approach in phase B.
The target colonisation frequency of 70% was chosen 
partly to be appropriate for future studies requiring 
a comparison of colonised participants with non-col-
onised/protected participants, for example, studies 
aiming to identify protective biomarkers. This coloni-
sation frequency might not be appropriate for studies 
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designed to assess the efficacy of novel vaccines in preven-
tion of colonisation where a near 100% colonisation 
frequency would be preferable. Therefore, the SI dose 
may be increased in future studies, depending on the 
results of this initial study.
We recognise that this method of intranasal inocula-
tion to induce colonisation/infection differs from the 
natural course of infection. However, this model will 
provide the opportunity to study the systemic and local 
immune response to exposure to Bp in a way that would 
not be feasible in natural human exposure or accurately 
represented by an animal model of exposure. Because 
of the atypical and often late presentation of pertussis 
in adults, knowledge about the features of presymptom-
atic and early infection is lacking. This study will give a 
unique insight in the initial interaction between bacteria 
and host during the first 2 weeks after initial exposure. 
The development of a safe human challenge model of 
pertussis, in conjunction with the recently developed 
baboon model of pertussis, has the potential to provide 
a path forward for answering critical questions about 
pertussis pathogenesis and host responses and will likely 
aid in the development of next-generation pertussis 
vaccines.35 Within the Periscope consortium, we aim to 
compare the results of this study with animal studies, 
vaccination studies with acellular and whole cell vaccines 
and natural infection studies with Bp.
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